메뉴 건너뛰기




Volumn 136, Issue 4, 2015, Pages 732-738

Safety and efficacy of direct oral anticoagulants compared to warfarin for extended treatment of venous thromboembolism -a systematic review and meta-analysis

Author keywords

Bleeding; New oral anticoagulants; Recurrent venous thromboembolism; Venous thromboembolism; Vitamin K antagonists

Indexed keywords

APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT;

EID: 84941875041     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2015.07.022     Document Type: Article
Times cited : (23)

References (32)
  • 2
    • 84906354978 scopus 로고    scopus 로고
    • Non-Vitamin K antagonist oral anticoagulants (NOACs): Clinical evidence and therapeutic considerations
    • K. Saraf, P. Morris, P. Garg, P. Sheridan, and R. Storey Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations Postgrad. Med. J. 90 1067 2014 520 528
    • (2014) Postgrad. Med. J. , vol.90 , Issue.1067 , pp. 520-528
    • Saraf, K.1    Morris, P.2    Garg, P.3    Sheridan, P.4    Storey, R.5
  • 3
    • 84894295323 scopus 로고    scopus 로고
    • Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis
    • S. Schulman, A.K. Kakkar, S.Z. Goldhaber, S. Schellong, H. Eriksson, P. Mismetti, and et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis Circulation 129 7 2014 764 772
    • (2014) Circulation , vol.129 , Issue.7 , pp. 764-772
    • Schulman, S.1    Kakkar, A.K.2    Goldhaber, S.Z.3    Schellong, S.4    Eriksson, H.5    Mismetti, P.6
  • 4
    • 84894222894 scopus 로고    scopus 로고
    • Treatment of venous thromboembolism
    • P.S. Wells, M.A. Forgie, and M.A. Rodger Treatment of venous thromboembolism JAMA 311 7 2014 717 728
    • (2014) JAMA , vol.311 , Issue.7 , pp. 717-728
    • Wells, P.S.1    Forgie, M.A.2    Rodger, M.A.3
  • 5
    • 84908270185 scopus 로고    scopus 로고
    • Evaluation of Oral Anticoagulants for the Extended Treatment of Venous Thromboembolism Using a Mixed-Treatment Comparison, Meta-Analytic Approach
    • B.M. Rollins, M.A. Silva, J.L. Donovan, and A.O. Kanaan Evaluation of Oral Anticoagulants for the Extended Treatment of Venous Thromboembolism Using a Mixed-Treatment Comparison, Meta-Analytic Approach Clin. Ther. 10 2014 1454 1464
    • (2014) Clin. Ther. , Issue.10 , pp. 1454-1464
    • Rollins, B.M.1    Silva, M.A.2    Donovan, J.L.3    Kanaan, A.O.4
  • 6
    • 84908349388 scopus 로고    scopus 로고
    • Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials
    • S.K. Kakkos, G.I. Kirkilesis, and I.A. Tsolakis Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials Eur. J. Vasc. Endovasc. Surg. 5 2014 565 575
    • (2014) Eur. J. Vasc. Endovasc. Surg. , Issue.5 , pp. 565-575
    • Kakkos, S.K.1    Kirkilesis, G.I.2    Tsolakis, I.A.3
  • 7
    • 84904533958 scopus 로고    scopus 로고
    • Risk assessment for recurrence and optimal agents for extended treatment of venous thromboembolism
    • G. Agnelli, and C. Becattini Risk assessment for recurrence and optimal agents for extended treatment of venous thromboembolism Hematol. Am. Soc. Hematol. Educ. Program 2013 2013 471 477
    • (2013) Hematol. Am. Soc. Hematol. Educ. Program , vol.2013 , pp. 471-477
    • Agnelli, G.1    Becattini, C.2
  • 9
    • 84884548759 scopus 로고    scopus 로고
    • Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: Systematic review and network meta-analysis
    • L.A. Castellucci, C. Cameron, G. Le Gal, M.A. Rodger, D. Coyle, P.S. Wells, and et al. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis BMJ 347 2013 f5133
    • (2013) BMJ , vol.347 , pp. f5133
    • Castellucci, L.A.1    Cameron, C.2    Le Gal, G.3    Rodger, M.A.4    Coyle, D.5    Wells, P.S.6
  • 10
    • 84859001212 scopus 로고    scopus 로고
    • The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
    • J.P. Higgins, D.G. Altman, P.C. Gotzsche, P. Juni, D. Moher, A.D. Oxman, and et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials BMJ 343 2011 d5928
    • (2011) BMJ , vol.343 , pp. d5928
    • Higgins, J.P.1    Altman, D.G.2    Gotzsche, P.C.3    Juni, P.4    Moher, D.5    Oxman, A.D.6
  • 11
    • 84872011968 scopus 로고    scopus 로고
    • The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration
    • A. Liberati, D.G. Altman, J. Tetzlaff, C. Mulrow, P.C. Gotzsche, J.P. Ioannidis, and et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration J. Clin. Epidemiol. 62 10 2009 e1 e34
    • (2009) J. Clin. Epidemiol. , vol.62 , Issue.10 , pp. e1-e34
    • Liberati, A.1    Altman, D.G.2    Tetzlaff, J.3    Mulrow, C.4    Gotzsche, P.C.5    Ioannidis, J.P.6
  • 15
    • 0035913237 scopus 로고    scopus 로고
    • Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators
    • G. Agnelli, P. Prandoni, M.G. Santamaria, P. Bagatella, A. Iorio, M. Bazzan, and et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators N. Engl. J. Med. 345 3 2001 165 169
    • (2001) N. Engl. J. Med. , vol.345 , Issue.3 , pp. 165-169
    • Agnelli, G.1    Prandoni, P.2    Santamaria, M.G.3    Bagatella, P.4    Iorio, A.5    Bazzan, M.6
  • 16
    • 0033602514 scopus 로고    scopus 로고
    • A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism
    • C. Kearon, M. Gent, J. Hirsh, J. Weitz, M.J. Kovacs, D.R. Anderson, and et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism N. Engl. J. Med. 340 12 1999 901 907
    • (1999) N. Engl. J. Med. , vol.340 , Issue.12 , pp. 901-907
    • Kearon, C.1    Gent, M.2    Hirsh, J.3    Weitz, J.4    Kovacs, M.J.5    Anderson, D.R.6
  • 18
    • 84880769850 scopus 로고    scopus 로고
    • Efficacy and safety of new oral anticoagulants for extended treatment of venous thromboembolism: Systematic review and meta-analyses of randomized controlled trials
    • P. Sardar, S. Chatterjee, and D. Mukherjee Efficacy and safety of new oral anticoagulants for extended treatment of venous thromboembolism: systematic review and meta-analyses of randomized controlled trials Drugs 73 11 2013 1171 1182
    • (2013) Drugs , vol.73 , Issue.11 , pp. 1171-1182
    • Sardar, P.1    Chatterjee, S.2    Mukherjee, D.3
  • 19
    • 84925011405 scopus 로고    scopus 로고
    • Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: Network meta-analysis
    • G. Alotaibi, K. Alsaleh, C. Wu, and M.S. McMurtry Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis Int. Angiol. 33 4 2014 301 308
    • (2014) Int. Angiol. , vol.33 , Issue.4 , pp. 301-308
    • Alotaibi, G.1    Alsaleh, K.2    Wu, C.3    McMurtry, M.S.4
  • 20
    • 8044235654 scopus 로고    scopus 로고
    • The Duration of Oral Anticoagulant Therapy after a Second Episode of Venous Thromboembolism
    • S. Schulman, S. Granqvist, M. Holmström, A. Carlsson, P. Lindmarker, P. Nicol, and et al. The Duration of Oral Anticoagulant Therapy after a Second Episode of Venous Thromboembolism N. Engl. J. Med. 336 6 1997 393 398
    • (1997) N. Engl. J. Med. , vol.336 , Issue.6 , pp. 393-398
    • Schulman, S.1    Granqvist, S.2    Holmström, M.3    Carlsson, A.4    Lindmarker, P.5    Nicol, P.6
  • 21
    • 23844472994 scopus 로고    scopus 로고
    • Evidence from clinical trials: Can we do better?
    • A.D. Siderowf Evidence from clinical trials: can we do better? NeuroRx 1 3 2004 363 371
    • (2004) NeuroRx , vol.1 , Issue.3 , pp. 363-371
    • Siderowf, A.D.1
  • 22
    • 84903775609 scopus 로고    scopus 로고
    • Phase III trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE: Comparison and critique of study methodology and results
    • A.T. Cohen, S. Imfeld, and T. Rider Phase III trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE: comparison and critique of study methodology and results Adv. Ther. 31 5 2014 473 493
    • (2014) Adv. Ther. , vol.31 , Issue.5 , pp. 473-493
    • Cohen, A.T.1    Imfeld, S.2    Rider, T.3
  • 23
    • 84895541979 scopus 로고    scopus 로고
    • Non-Vitamin K antagonist oral anticoagulants in cardiovascular disease management: Evidence and unanswered questions
    • J.W. Cheng, and G. Barillari Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions J. Clin. Pharm. Ther. 39 2 2014 118 135
    • (2014) J. Clin. Pharm. Ther. , vol.39 , Issue.2 , pp. 118-135
    • Cheng, J.W.1    Barillari, G.2
  • 24
    • 84876226603 scopus 로고    scopus 로고
    • New oral anticoagulants: Comparative pharmacology with Vitamin K antagonists
    • F. Scaglione New oral anticoagulants: comparative pharmacology with vitamin K antagonists Clin. Pharmacokinet. 52 2 2013 69 82
    • (2013) Clin. Pharmacokinet. , vol.52 , Issue.2 , pp. 69-82
    • Scaglione, F.1
  • 25
    • 84927518854 scopus 로고    scopus 로고
    • The treatment of venous thromboembolism with novel oral anticoagulants: Warnings and limitations
    • P. Prandoni The treatment of venous thromboembolism with novel oral anticoagulants: warnings and limitations Blood Transfus. 13 2 2015 178 180
    • (2015) Blood Transfus. , vol.13 , Issue.2 , pp. 178-180
    • Prandoni, P.1
  • 26
    • 84904764432 scopus 로고    scopus 로고
    • Novel oral anticoagulants in patients with renal insufficiency: A meta-analysis of randomized trials
    • P. Sardar, S. Chatterjee, E. Herzog, R. Nairooz, D. Mukherjee, and J.L. Halperin Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials Can. J. Cardiol. 30 8 2014 888 897
    • (2014) Can. J. Cardiol. , vol.30 , Issue.8 , pp. 888-897
    • Sardar, P.1    Chatterjee, S.2    Herzog, E.3    Nairooz, R.4    Mukherjee, D.5    Halperin, J.L.6
  • 27
    • 33748622029 scopus 로고    scopus 로고
    • New concepts in optimal management of anticoagulant therapy for extended treatment of venous thromboembolism
    • S. Schulman, and M. Ogren New concepts in optimal management of anticoagulant therapy for extended treatment of venous thromboembolism Thromb. Haemost. 96 3 2006 258 266
    • (2006) Thromb. Haemost. , vol.96 , Issue.3 , pp. 258-266
    • Schulman, S.1    Ogren, M.2
  • 29
    • 84907221429 scopus 로고    scopus 로고
    • Clinical and safety outcomes associated with treatment of acute venous thromboembolism: A systematic review and meta-analysis
    • L.A. Castellucci, C. Cameron, G. Le Gal, M.A. Rodger, D. Coyle, P.S. Wells, and et al. Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis JAMA 312 11 2014 1122 1135
    • (2014) JAMA , vol.312 , Issue.11 , pp. 1122-1135
    • Castellucci, L.A.1    Cameron, C.2    Le Gal, G.3    Rodger, M.A.4    Coyle, D.5    Wells, P.S.6
  • 32
    • 78049398953 scopus 로고    scopus 로고
    • Systematic review and meta-analysis methodology
    • M. Crowther, W. Lim, and M.A. Crowther Systematic review and meta-analysis methodology Blood 116 17 2010 3140 3146
    • (2010) Blood , vol.116 , Issue.17 , pp. 3140-3146
    • Crowther, M.1    Lim, W.2    Crowther, M.A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.